TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
AstraZeneca ( (GB:AZN) ) has shared an announcement.
AstraZeneca’s Imfinzi (durvalumab) has been approved in the US as the first perioperative immunotherapy for early-stage gastric and gastroesophageal junction cancers, based on the MATTERHORN Phase III trial results. This approval, which follows a Priority Review by the FDA, marks a significant advancement in the treatment of these cancers, offering a new standard of care with a notable survival benefit. The Imfinzi regimen, combined with FLOT chemotherapy, demonstrated a 29% reduction in disease progression risk and a 22% reduction in death risk compared to chemotherapy alone, establishing a new clinical paradigm and providing renewed hope for patients.
The most recent analyst rating on (GB:AZN) stock is a Sell with a £105.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on GB:AZN Stock
According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.
AstraZeneca’s strong financial performance and positive earnings call are the primary drivers of its stock score. The company’s robust revenue growth, high profitability, and strategic progress in key markets are significant strengths. However, the high valuation and some cash flow management challenges slightly temper the overall score.
To see Spark’s full report on GB:AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in oncology, cardiovascular, renal, and metabolism, and respiratory and immunology. The company has a significant presence in the oncology sector, with a strong emphasis on developing innovative treatments for various types of cancer.
Average Trading Volume: 2,030,048
Technical Sentiment Signal: Buy
Current Market Cap: £216B
For a thorough assessment of AZN stock, go to TipRanks’ Stock Analysis page.